Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 760

recruiting
3 968
countries
28
conditions
2 103

10 282 trials match your criteria

Schizophrenia

Not recruiting

Study on the Safety and Tolerability of Cariprazine for Treating Schizophrenia in Adolescents Aged 13-17

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years
  • Substances:Cariprazine

Study of Lecanemab (BAN2401) Treatment in People with Early Alzheimer's Disease: Testing Safety and Effectiveness Over 18 Months

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lecanemab

Neoplasm

Not recruiting

Study on Vemurafenib for Patients with Advanced Cancers with BRAF Gene Changes

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Vemurafenib

Study of Sacituzumab Govitecan, Pembrolizumab, and a Platinum Drug Combination for Advanced Non-Small Cell Lung Cancer Patients Without Genomic Alterations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Colour blindness

Not recruiting

Study on the Safety and Effectiveness of rAAV.hCNGA3 for Adults and Minors with CNGA3-Linked Achromatopsia

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Adeno-Associated Viral Vector Serotype 8 Containing The Human Cnga3 Gene Under The Control Of A Cone Arrestin Promoter

Study on Trastuzumab and Pertuzumab for Patients with HER2-Positive Breast Cancer Using a Response-Adapted Strategy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Ischaemic stroke

Not recruiting

Study on the Safety and Effectiveness of LT3001 for Patients with Acute Ischemic Stroke

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:LT3001

Study on the Safety and Effectiveness of Lutetium (177Lu) Vipivotide Tetraxetan for Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177LU) vipivotide tetraxetan

Study on the Safety and Effectiveness of ABSK021 for Patients with Tenosynovial Giant Cell Tumor

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ABSK021 hydrochloride hydrate

Plasma cell myeloma

Not recruiting

Study Comparing Idecabtagene Vicleucel and Lenalidomide Maintenance Therapy for Adults with Newly Diagnosed Multiple Myeloma After Stem Cell Transplant

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide

Neoplasm malignant

Not recruiting

Study on the Effectiveness of Autologous Tumor-Infiltrating Lymphocytes, Aldesleukin, Fludarabine Phosphate, and Cyclophosphamide in Advanced Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin

Study on Regorafenib and Nivolumab for Patients with Advanced Gastro-Oesophageal Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.